Statement of Principles concerning autosomal dominant polycystic kidney disease (Reasonable Hypothesis) (No. 35 of 2023)

Administered by Department of Veterans' Affairs

Legislation au F2023L00483 In force Legislative Instrument

Legislation content

EXPLANATORY STATEMENT

 

STATEMENT OF PRINCIPLES CONCERNING

AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE

(REASONABLE HYPOTHESIS) (NO. 35 OF 2023)

 

VETERANS' ENTITLEMENTS ACT 1986

MILITARY REHABILITATION AND COMPENSATION ACT 2004

 

  1. This is the Explanatory Statement to the Statement of Principles concerning Autosomal dominant polycystic kidney disease (Reasonable Hypothesis) (No. 35 of 2023).

Background

2.             The Repatriation Medical Authority (the Authority), under subsection 196B(8) of the Veterans' Entitlements Act 1986 (the VEA), repeals Instrument No. 39 of 2015 (Federal Register of Legislation No.  F2015L00004) determined under subsection 196B(2) of the VEA concerning Autosomal dominant polycystic kidney disease.

3.             The Authority is of the view that there is sound medical-scientific evidence that indicates that Autosomal dominant polycystic kidney disease and death from Autosomal dominant polycystic kidney disease can be related to particular kinds of service.  The Authority has therefore determined pursuant to subsection 196B(2) of the VEA a Statement of Principles concerning Autosomal dominant polycystic kidney disease (Reasonable Hypothesis) (No. 35 of 2023).  This Instrument will in effect replace the repealed Statement of Principles.

Purpose and Operation

4.             The Statement of Principles will be applied in determining claims under the VEA and the Military Rehabilitation and Compensation Act 2004 (the MRCA).

5.             The Statement of Principles sets out the factors that must as a minimum exist, and which of those factors must be related to the following kinds of service rendered by a person:

 operational service under the VEA;

 peacekeeping service under the VEA;

 hazardous service under the VEA;

 British nuclear test defence service under the VEA;

 warlike service under the MRCA;

 non-warlike service under the MRCA,

before it can be said that a reasonable hypothesis has been raised connecting Autosomal dominant polycystic kidney disease or death from Autosomal dominant polycystic kidney disease, with the circumstances of that service.  The Statement of Principles has been determined for the purposes of both the VEA and the MRCA.

6.             This Instrument results from an investigation notified by the Authority in the Government Notices Gazette of 10 May 2022 concerning Autosomal dominant polycystic kidney disease in accordance with section 196G of the VEA.  The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.

7.             The contents of this Instrument are in similar terms as the repealed Instrument.  Comparing this Instrument and the repealed Instrument, the differences include:

  • adopting the latest revised Instrument format, which commenced in 2015;
  • specifying a day of commencement for the Instrument in section 2;
  • revising the definition of 'Autosomal dominant polycystic kidney disease' in subsection 7(2);
  • including ICD-10-AM codes for 'Autosomal dominant polycystic kidney disease' in subsection 7(3);
  • revising the reference to 'ICD-10-AM code' in subsection 7(4);

 

Consultation

8.             Prior to determining this Instrument, the Authority advertised its intention to undertake an investigation in relation to Autosomal dominant polycystic kidney disease in the Government Notices Gazette of 10 May 2022, and circulated a copy of the notice of intention to investigate to a wide range of organisations representing veterans, service personnel and their dependants.  The Authority invited submissions from the Repatriation Commission, the Military Rehabilitation and Compensation Commission, organisations and persons referred to in section 196E of the VEA, and any person having expertise in the field.  No submissions were received for consideration by the Authority in relation to the investigation.

Human Rights

9.             This instrument is compatible with the Human Rights and Freedoms recognised or declared in the International Instruments listed in Section 3 of the Human Rights (Parliamentary Scrutiny) Act 2011.  A Statement of Compatibility with Human Rights follows.

Finalisation of Investigation

10.         The determining of this Instrument finalises the investigation in relation to Autosomal dominant polycystic kidney disease as advertised in the Government Notices Gazette of 10 May 2022.

References

11.         A list of references relating to the above condition is available on the Authority's website at: www.rma.gov.au. Any other document referred to in this Statement of Principles is available on request to the Repatriation Medical Authority at the following address:

              

Email:    info@rma.gov.au

Post:      The Registrar

Repatriation Medical Authority

GPO Box 1014

BRISBANE    QLD    4001


Statement of Compatibility with Human Rights

(Prepared in accordance with Part 3 of the Human Rights (Parliamentary Scrutiny) Act 2011)

 

Instrument No.:   Statement of Principles No. 35 of 2023

Kind of Injury, Disease or Death: Autosomal dominant polycystic kidney disease

 

This Legislative Instrument is compatible with the human rights and freedoms recognised or declared in the international instruments listed in section 3 of the Human Rights (Parliamentary Scrutiny) Act 2011.

Overview of the Legislative Instrument

1. This Legislative Instrument is determined pursuant to subsection 196B(2) of the Veterans' Entitlements Act 1986 (the VEA) for the purposes of the VEA and the Military Rehabilitation and Compensation Act 2004 (the MRCA).  Part XIA of the VEA requires the determination of these instruments outlining the factors connecting particular kinds of injury, disease or death with service such being determined solely on the available sound medical-scientific evidence.

2. This Legislative Instrument:-

  • facilitates claimants in making, and the Repatriation Commission and the Military Rehabilitation and Compensation Commission in assessing, claims under the VEA and the MRCA respectively, by specifying the circumstances in which medical treatment and compensation can be extended to eligible persons who have Autosomal dominant polycystic kidney disease;
  • facilitates the review of such decisions by the Veterans' Review Board and the Administrative Appeals Tribunal;
  • outlines the factors which the current sound medical-scientific evidence indicates must as a minimum exist, before it can be said that a reasonable hypothesis has been raised, connecting Autosomal dominant polycystic kidney disease with the circumstances of eligible service rendered by a person, as set out in clause 5 of the Explanatory Statement;
  • replaces Instrument No. 39 of 2015; and
  • reflects developments in the available sound medical-scientific evidence concerning Autosomal dominant polycystic kidney disease which have occurred since that earlier instrument was determined. 

3. The Instrument is assessed as being a technical instrument which improves the medico-scientific quality of outcomes under the VEA and the MRCA. 

Human Rights Implications

4. This Legislative Instrument does not derogate from any human rights. It promotes the human rights of veterans, current and former Defence Force members as well as other persons such as their dependents, including:

  • the right to social security (Art 9, International Covenant on Economic, Social and Cultural Rights; Art 26, Convention on the Rights of the Child and Art 28, Convention on the Rights of Persons with Disabilities) by helping to ensure that the qualifying conditions for the benefit are 'reasonable, proportionate and transparent'[1];
  • the right to an adequate standard of living (Art 11, ICESCR; Art 27, CRC and Art 28, CRPD) by facilitating the assessment and determination of social security benefits;
  • the right to the enjoyment of the highest attainable standard of physical and mental health (Art 12, ICESCR and Art 25, CRPD), by facilitating the assessment and determination of compensation and benefits in relation to the treatment and rehabilitation of veterans and Defence Force members;
  • the rights of persons with disabilities by facilitating the determination of claims relating to treatment and rehabilitation (Art 26, CRPD); and
  • ensuring that those rights "will be exercised without discrimination of any kind as to race, colour, sex, language, religion, political or other opinion, national or social origin, property, birth or other status" (Art 2, ICESCR).

Conclusion

This Legislative Instrument is compatible with human rights as it does not derogate from and promotes a number of human rights.

 

Repatriation Medical Authority

 

 

 

 

 

[1] In General Comment No. 19 (The right to social security), the Committee on Economic, Social and Cultural Rights said (at paragraph 24) this to be one of the elements of ensuring accessibility to social security.

Overview

The Statement of Principles concerning Autosomal dominant polycystic kidney disease (Reasonable Hypothesis) (No. 35 of 2023) was enacted to address the need for a clear framework governing the assessment of claims related to Autosomal dominant polycystic kidney disease (ADPKD) among veterans and current or former Defence Force members. This legislation, determined under subsection 196B(2) of the Veterans' Entitlements Act 1986 (VEA) by the Repatriation Medical Authority, repeals the previous Statement of Principles No. 39 of 2015 and incorporates the latest medical-scientific evidence. Its primary objective is to facilitate the claims process by setting out the factors that must exist, linking ADPKD to specific service types, thereby enabling the Repatriation Commission and the Military Rehabilitation and Compensation Commission to assess and determine eligibility for medical treatment and compensation. This instrument ensures that the principles applied are both reasonable and based on sound medical-scientific evidence, promoting the human rights of affected individuals in accordance with international human rights instruments. This legislative instrument is designed to streamline the claims process and enhance the quality of medico-scientific outcomes under the VEA and the Military Rehabilitation and Compensation Act 2004 (MRCA), ensuring that the rights of veterans, current and former Defence Force members, and their dependents are protected and exercised without discrimination.

Scope and Application

The Statement of Principles concerning Autosomal dominant polycystic kidney disease (Reasonable Hypothesis) (No. 35 of 2023) applies to veterans and current or former members of the Defence Force who may have contracted Autosomal dominant polycystic kidney disease (ADPKD) as a result of their service, and to their dependents. This instrument, determined under subsection 196B(2) of the Veterans' Entitlements Act 1986 (VEA) and the Military Rehabilitation and Compensation Act 2004 (MRCA), sets out the minimum factors that must be present to establish a reasonable hypothesis linking ADPKD to particular kinds of service. The kinds of service covered include operational, peacekeeping, hazardous, British nuclear test defence, warlike, and non-warlike service. The instrument is designed to facilitate the assessment and determination of claims under both the VEA and the MRCA, ensuring that claimants and the relevant commissions have clear guidelines based on the latest sound medical-scientific evidence. The instrument replaces a previous version, Instrument No. 39 of 2023, and incorporates updated definitions and coding, while maintaining compatibility with human rights as recognised in international instruments. This instrument does not specify any exclusions, exemptions, or thresholds but allows for its application to be extended or restricted through subordinate instruments if necessary.

Key Provisions

The Statement of Principles concerning Autosomal dominant polycystic kidney disease (Reasonable Hypothesis) (No. 35 of 2023) outlines the specific circumstances in which a reasonable hypothesis can be raised connecting this condition or death from it with particular kinds of service (sections 2 and 5). The kinds of service covered include operational, peacekeeping, hazardous, and British nuclear test defence service under the Veterans' Entitlements Act 1986, as well as warlike and non-warlike service under the Military Rehabilitation and Compensation Act 2004. The document specifies the factors that must exist and be related to the service in question for such a hypothesis to be considered reasonable (section 5). It also includes the latest revisions to the definition of Autosomal dominant polycystic kidney disease and the relevant ICD-10-AM codes (subsections 7(2) and 7(3)). The Statement of Principles will facilitate the assessment and determination of claims for medical treatment and compensation by veterans, service personnel, and their dependents. The Act imposes obligations on the Repatriation Medical Authority to determine Statements of Principles based on sound medical-scientific evidence, ensuring that these instruments are updated to reflect the latest available evidence (subsection 196B(2) of the Veterans' Entitlements Act 1986). It also requires the Authority to advertise its intention to investigate and consult with relevant stakeholders, including veterans' organisations and those with expertise in the field (sections 8 and 9). The Act further mandates that the Authority ensures these instruments are compatible with human rights and freedoms recognised in international instruments (section 9). The Statement of Principles does not explicitly outline offences, penalties, or civil/criminal consequences for breach. However, non-compliance with the requirements to determine and update these instruments, or failure to ensure they are compatible with human rights, could potentially lead to legal challenges or reviews by the relevant authorities, including the Administrative Appeals Tribunal and the Veterans' Review Board. These bodies would assess the validity and application of the Statement of Principles in individual claims, ensuring that the rights of claimants are protected and that the principles are applied fairly and accurately.

Legal classification tags

Area of Law
Veterans' Law
Instrument
Statement of Principles
Concepts
Definitions & Interpretation
Regulatory Standards
Consultation Requirements

Interactions

Authorises

All Versions

Sourced from the Federal Register of Legislation at 26 August 2026. For the latest information on Australian Government law please go to https://www.legislation.gov.au.